Wednesday, May 21st: 8:30am-5:45 pm @ the CR-CHUM SESSION 1: IBD disease risk. Co-chairs: Marika Sarfati (CR-CHUM) et François Boudreau (Université de Sherbrooke) PLENARY: Mark J. Daly, Broad Institute & Massachusetts General Hospital Invited talk: Corinne Maurice, McGill University Invited talk: Martin Pelletier, Université Laval Trainee presentation: to be selected from abstracts Panel discussion (all presentersContinue reading “Quebec IBD Research Conference – Preliminary Program –”
Author Archives: John Rioux
IBD Genomic Medicine Consortium
A Brief History: The iGenoMed Consortium was created in 2012 to take full advantage of existing and emerging genomic technologies and apply these to powerful retrospective and prospective cohorts to better understand the biological differences between patients with IBD and to develop precision medicine approaches to improve diagnosis and treatment of IBD, and to advanceContinue reading “IBD Genomic Medicine Consortium”
iGenoMed-MTT: A Prospective Multi-omic Clinical Study of Response to Molecularly-Targeted Therapies in IBD
Project Summary: At the core of the iGenoMed-MTT Project is a multi-center prospective clinical study of response to advanced therapies in IBD. Biological samples are taken just prior to initiation of a Molecularly Targeted Therapy or MTT as well as at the first follow-up visit when an individual’s response is assessed. In this study, patientsContinue reading “iGenoMed-MTT: A Prospective Multi-omic Clinical Study of Response to Molecularly-Targeted Therapies in IBD”
Quebec IBD Genetics Consortium
(1996-2017) Brief History. The Quebec IBD Genetics Consortium (QIGC) has its origins (1996-2002) in a group of five academic clinical centers that collected DNA samples and clinical information for IBD genetics projects. In 2002, it played an integral part in the creation of the North American IBD Genetics Consortium (IBDGC), which was constituted by six different centersContinue reading “Quebec IBD Genetics Consortium”
Uncover the biological heterogeneity that is at the basis of clinical heterogeneity in IBD, and develop powerful diagnostic and prognostic biomarkers & tools.
We aim to unravel the biological heterogeneity of CD and UC using genetic, genomic and immunologic profiling of patient blood and stool samples and a subset with intestinal biopsies/surgical specimens, with a particular focus on incident cases of CD and in longitudinal studies of response to therapy in CD and UC. This enables us toContinue reading “Uncover the biological heterogeneity that is at the basis of clinical heterogeneity in IBD, and develop powerful diagnostic and prognostic biomarkers & tools.”